Download IV Vitamin C in Cancer

Historical papers: 40 Years ago……
Proc Natl Acad Sci U S A. 1978 Sep;75(9):4538-42.
Supplemental ascorbate in the supportive treatment of cancer: re-evaluation of prolongation of
survival times in terminal human cancer.
Cameron E, Pauling L.
Abstract
A study has been made of the survival times of 100 terminal cancer patients who were given
supplemental ascorbate, usually 10 g/day, as part of their routine management and 1000 matched
controls, similar patients who had received the same treatment except for the ascorbate. The two sets
of patients were in part the same as those used in our earlier study [Cameron, E. & Pauling, L. (1976)
Proc. Natl. Acad. Sci. USA 73, 3685-3689]. Tests confirm that the ascorbate-treated patients and the
matched controls are representative subpopulations of the same population of "untreatable" patients.
Survival times were measured not only from the date of "untreatability" but also from the precisely
known date of first hospital attendance for the cancer that eventually reached the terminal stage.
The ascorbate-treated patients were found to have a mean survival time about 300 days greater than
that of the controls. Survival times greater than 1 yr after the date of untreatability were observed for
22% of the ascorbate-treated patients and for 0.4% of the controls. The mean survival time of these
22 ascorbate-treated patients is 2.4 yr after reaching the apparently terminal stage; 8 of the
ascorbate-treated patients are still alive, with a mean survival time after untreatability of 3.5 yr.
PMID:279931[PubMed - indexed for MEDLINE] PMCID:PMC336151Free PMC Article
And 25 years ago ……
Med Hypotheses. 1991 Nov;36(3):185-9.
Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in
incurable cancer.
Cameron E1, Campbell A. Author information 1Vale of Leven Hospital, Alexandria, Scotland, UK.
Abstract
A computerized data bank was created recording the details of all cancer patients attending three
district general hospitals in West Central Scotland over a 4.5 year period 1978-1982.
At the conclusion of the trial, the records of 2804 individual patients were available for study, of whom
1826 had reached an incurable stage. 294 of these incurable cancer patients had received
supplemental ascorbate at some stage in their illness, whereas 1532 had not, and served as controls.
Analysis showed that the ascorbate-supplemented patients had a median overall survival time (343
days) almost double that of the controls (180 days). Our difficulties in having this simple, but
important, observation published are briefly recounted in the introduction
The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid
supplements in advanced human cancer.
Cameron E, Campbell A.
Chem Biol Interact. 1974 Oct;9(4):285-315. No abstract available.
Some References for IV Vitamin C Treatment in Cancer
Research combining IV Vitamin C with chemotherapy shows Improved Results and Outcomes
(Copy these into www.pubmed.com to find research article)
Docetaxel combined with IV Vitamin C shows enhanced benefit:
. Fromberg, A, et.al. Ascorbate Exerts anti-proliferative effects through cell cycle inhibition and
sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol, 67:1157-1166,
2011. DOI 10.1007/s00280-010-1418-6 (Springer online).
Carboplatin combined with IV Vitamin C shows enhanced benefit and outcomes:
. Sullivan, G. et. al. (2011, November). Prospective Randomized Phase I/IIa Pilot Trial to Assess
Safety and Benefit Administering High Dose Intravenous Ascorbate in Combination with
Chemotherapy in Newly Diagnosed Advanced Stage III or Stage IV Ovarian Cancer. Moderated
Abstract [6] presented at the Society for Integrative Oncology, Cleveland, OH.
Ma, Y. Drisko, J. Poilreddy, K. (2011, November). Synergistic Effects of Ascorbate with
Carboplatin against Human Ovarian Cancer in Vitro and in Vivo. Moderated Abstract [20]
presented at the Society for Integrative Oncology, Cleveland, OH.
Pathak A, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti B, et al. Chemotherapy alone vs.
chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell
lung cancer. J Am Coll Nutr 2005;24:16–21.
Yonsei Med J. 2015 Sep;56(5):1449-52. doi: 10.3349/ymj.2015.56.5.1449.
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from
Hepatocellular Carcinoma.
Seo MS1,2, Kim JK3, Shim JY4.
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M.
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug
to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9.
Epub 2005 Sep 12.
. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer:
Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A.
1976;73(10):3685-3689.
Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the
treatment of patients with advanced cancer. Anticancer Res. 2009;29(3):809-815. (PubMed)
Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively
kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U
S A. 2005;102(38):13604-13609. (PubMed)
Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively
generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad
Sci U S A. 2007;104(21):8749-8754. (PubMed)
. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and
decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A.
2008;105(32):11105-11109. (PubMed)
Riordan HD, Casciari JJ, Gonzalez MJ, et al. A pilot clinical study of continuous intravenous
ascorbate in terminal cancer patients. P R Health Sci J. 2005;24(4):269-276. (PubMed)
Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced
malignancy. Ann Oncol. 2008;19(11):1969-1974. (PubMed)
Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in
combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
PLoS One. 2012;7(1):e29794. (PubMed)
Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety,
tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with
advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139-146. (PubMed)
Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C
administration improves quality of life in breast cancer patients during chemo-/radiotherapy
and aftercare: results of a retrospective, multicentre, epidemiological cohort study in
Germany. In Vivo. 2011;25(6):983-990. (PubMed)
1
P R Health Sci J. 2004 Jun;23(2):115-8.Intravenous vitamin C as a chemotherapy agent: a report
on clinical cases.
Riordan HD1, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM,
Miranda-Massari JR, Rosario N, Rivera A.
Anticancer Res. 2009 Mar;29(3):809-15. High-dose vitamin C (ascorbic acid) therapy in the
treatment of patients with advanced cancer.
Ohno S1, Ohno Y, Suzuki N, Soma G, Inoue M.
Integr Cancer Ther. 2005 Mar;4(1):32-44.
Orthomolecular oncology review: ascorbic acid and cancer 25 years later.
González MJ1, Miranda-Massari JR, Mora EM, Guzmán A, Riordan NH, Riordan HD, Casciari JJ,
Jackson JA, Román-Franco A.